Tanning Peptides: Melanotan I, II, and PT-141 Research | Quantum Labs

The melanocortin peptide family

Melanotan I, Melanotan II, and PT-141 (bremelanotide) all belong to a small family of synthetic peptides based on alpha-melanocyte-stimulating hormone (α-MSH) — the natural peptide that triggers melanin production in skin cells. The three compounds occupy different positions in the regulatory landscape and serve different research purposes, despite the shared chemical lineage. This article walks through what each compound is, what published research has examined, and where each sits within the Australian regulatory framework.

Important compliance note up front: Melanotan I and Melanotan II are prohibited under Australian therapeutic and consumer-supply frameworks. Quantum Labs does not stock either compound. This article is educational content explaining what the research literature documents and why the regulatory position is what it is — not a purchase guide. For PT-141, which is also a melanocortin peptide but with a different research profile and different regulatory status, we do supply research-grade material.

The biology: why these peptides cause tanning

Skin pigmentation is regulated by melanocytes — pigment cells in the basal layer of the epidermis. Melanocytes produce melanin (the pigment that darkens skin) in response to signals binding the melanocortin-1 receptor (MC1R). Natural α-MSH is the primary endogenous MC1R agonist; UV exposure triggers α-MSH release, which drives the tanning response.

The synthetic α-MSH analogues — Melanotan I, Melanotan II, and PT-141 — were developed to study and modulate the melanocortin pathway. They differ in receptor selectivity, stability, and the specific aspects of melanocortin signalling they target:

• Melanocortin-1 receptor (MC1R) drives melanin production and the tanning response in skin.
• Melanocortin-3 and -4 receptors (MC3R, MC4R) are predominantly central nervous system receptors involved in appetite regulation, sexual response, and other systemic effects.
• Melanocortin-5 receptor (MC5R) is expressed primarily in exocrine glands.

The five receptors share substantial homology, so most synthetic α-MSH analogues activate multiple receptors rather than just one. This non-selectivity is the source of both the research interest and the side-effect concerns.

Melanotan I (afamelanotide)

Melanotan I — also known as afamelanotide and marketed internationally under the brand name Scenesse — is a synthetic α-MSH analogue with modifications that improve stability over native α-MSH.

• Receptor profile: Predominantly MC1R. Relatively selective for the tanning-related receptor compared to Melanotan II.
• Approval status globally: Approved in the EU, US, and several other jurisdictions as Scenesse for erythropoietic protoporphyria (EPP) — a rare genetic condition where patients have extreme light sensitivity. The therapeutic role is photoprotection in EPP, not cosmetic tanning.
• Australian status: Not approved as an ARTG-listed therapeutic in Australia. The Therapeutic Goods Administration prohibits its supply for cosmetic (tanning) use; the TGA has consistently warned against purchase or use of the compound from non-approved channels.
• Research-supply status in Australia:Restricted — the regulatory framing places it outside the standard research-supply pathway that other research peptides operate within.

Melanotan II

Melanotan II is a cyclic synthetic α-MSH analogue that is substantially less receptor-selective than Melanotan I — activating MC1R (tanning), MC3R, MC4R, and MC5R with broad potency. The reduced selectivity drives a much wider side-effect profile.

• Receptor profile: Broad agonist across MC1R, MC3R, MC4R, MC5R. Activates multiple pathways simultaneously.
• Documented effects in research: Tanning (MC1R), appetite suppression (MC4R), sexual arousal (MC4R), nausea, flushing, and skin darkening including of moles and freckles. Long-term safety data is very limited.
• Approval status: Not approved for any therapeutic indication in any jurisdiction. Has never completed the regulatory trial process.
• Australian status: Prohibited under the Therapeutic Goods Administration framework for cosmetic supply, and not available through any legitimate therapeutic or research-supply channel in Australia. The TGA has issued repeated warnings about Melanotan II, citing both the lack of safety data and the appearance of counterfeit product on the consumer market.
• Why the TGA position is strong: The combination of broad non-selectivity, no approval pathway, limited safety data, and active consumer-market sale of counterfeit material (rather than research-grade supply) puts Melanotan II in a different regulatory category than most research peptides.

Quantum Labs does not stock Melanotan II. The compound appears in our previous content and our SEO research data because it's widely searched for in Australia, but the regulatory and safety situation make it a compound we don't supply.

PT-141 (bremelanotide)

PT-141, also called bremelanotide, is a different melanocortin-pathway peptide. It was developed specifically as a research compound targeting the central melanocortin system — particularly MC3R and MC4R — rather than as a tanning compound. The receptor selectivity profile is fundamentally different to Melanotan I or II.

• Receptor profile: Predominantly MC3R and MC4R agonist. Limited MC1R activity, so it doesn't drive significant tanning effects.
• Research focus: Central melanocortin pathway — particularly sexual-response signalling. The largest body of research literature covers MC4R-mediated effects on sexual arousal in pre-clinical and clinical studies.
• Approval status: Approved in the US under the brand name Vyleesi for hypoactive sexual desire disorder (HSDD) in pre-menopausal women. The first FDA-approved central melanocortin agonist.
• Australian status: Not approved as an ARTG-listed therapeutic in Australia. Restricted for compounded therapeutic supply. Available for research and laboratory use without therapeutic representation — the standard research-supply pathway.

Quantum Labs supplies research-grade PT-141 for laboratory research applications, HPLC-verified to ≥99% purity and shipped from Australian stock.

Why Melanotan and PT-141 sit in different regulatory categories

A reasonable question: if Melanotan II and PT-141 are both α-MSH analogues, why is one prohibited and the other available for research use? Three reasons:

• Selectivity profile. Melanotan II is a broad melanocortin agonist with substantial off-target activity across all the melanocortin receptors. PT-141 is more selective for the central MC3R/MC4R signal. Narrower mechanism = narrower side-effect profile.
• Research depth. PT-141 has been the subject of substantial controlled human clinical trials, culminating in FDA approval for HSDD. Melanotan II has never been formally trialled for any human therapeutic indication — its supply has historically been through consumer channels rather than research or therapeutic ones.
• Market context. Melanotan II appears heavily in counterfeit consumer-supply channels in Australia — gym networks, beauty salons, online consumer-direct sales — which puts it outside the research-supply framework that pharmaceutical-grade research peptides operate within. PT-141 is supplied through legitimate research channels with batch-level QC and certificate of analysis traceability.

The TGA's regulatory differentiation isn't arbitrary — it reflects substantive differences in mechanism, evidence base, and supply chain integrity.

What the “melanotan nasal spray” search reflects

A substantial fraction of Australian Melanotan searches specifically reference nasal spray delivery. The reason is historical: in the unofficial consumer-supply context, intranasal delivery is positioned as a less-invasive alternative to subcutaneous injection. The compound delivered is typically the same — Melanotan II or counterfeit material claimed to be Melanotan II — just in a different format.

From a research perspective, intranasal delivery is a standard delivery format for several peptide categories (Semax and Selank, notably). The intranasal route is mechanistically reasonable for compounds with appropriate absorption properties. The issue with Melanotan-2 nasal sprays in Australia isn't the delivery format — it's the underlying compound, its lack of approval, and the unofficial supply chains involved.

PT-141 also appears in intranasal formulations in some research designs. The FDA approval (as Vyleesi) is for subcutaneous injection, but intranasal research has also been published. For research-grade PT-141 reconstitution generally, see our reconstitution guide.

The Melanotan 1 vs Melanotan 2 question

One of the more-searched comparisons in this space. The short version:

• Melanotan I (afamelanotide): Approved therapeutic in several jurisdictions for EPP. Not approved in Australia. More receptor-selective (predominantly MC1R). Substantially deeper clinical evidence base.
• Melanotan II: No approval anywhere. Broad non-selective melanocortin agonist. Prohibited in Australia. Wider side-effect profile.

The two compounds are sometimes treated as interchangeable in consumer-market discussions but they're structurally distinct molecules with different research and regulatory histories. The conflation in casual discussion adds to the general confusion around the melanocortin peptide category.

The honest position for Australian researchers

If you're an Australian researcher whose work touches the melanocortin pathway, the practical position is:

• For central melanocortin (MC3R/MC4R) research — PT-141 is the available research-grade compound in Australia. Its receptor selectivity makes it a more informative research tool than the broader Melanotan family anyway.
• For peripheral MC1R (tanning) research — Australian research-supply pathways don't cover Melanotan I or II. Researchers needing these compounds for legitimate research work typically source through international research-supply channels with appropriate import permits or work with synthetic α-MSH directly.
• For cosmetic tanning use — these compounds are not a legitimate option in Australia. The TGA position is firm, and the consumer-market supply is substantially contaminated with counterfeit material. Research-supply pathways are not a workaround for cosmetic use.

Broader context

The melanocortin peptide family illustrates an important principle in research peptide supply: the regulatory framework distinguishes between compounds based on multiple criteria — approval status, mechanism, evidence base, and supply-chain integrity — not just chemical similarity. PT-141 and Melanotan II share an ancestry but occupy completely different regulatory categories in Australia, and the differentiation is substantive rather than arbitrary.

For more on how the Australian regulatory frame applies across the broader peptide market, see our peptide legality guide. For broader safety considerations across the research peptide family, see our peptide safety overview.